Medicare Overpaid $15 Million for Roche Cancer Drug, OIG Says

Medicare, the U.S. health insurance program for the elderly and disabled, overpaid for Roche Holding AG’s Herceptin breast-cancer treatment by about $15 million, according to a government investigation.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.